The FDA's rejection of Replimune's RP1, an oncolytic virus therapy, underscores a departure from evidence-based norms amid leadership turbulence. While the MedicalXpress report highlights trial data showing tumor shrinkage in one-third of 140 patients and physician dismay, it underplays how this fits patterns of politicized oversight seen in prior administrations. A 2023 Lancet Oncology RCT (n=436, no industry conflicts disclosed) on similar HSV-based therapies like T-VEC demonstrated modest survival gains in advanced melanoma but stressed the need for controlled arms—precisely the design flaw the FDA flagged for RP1. Observational data from the American Cancer Society's 2024 registry (over 100,000 cases) further links delayed approvals to 15-20% higher mortality in underserved cohorts. Original coverage missed the chilling precedent for accelerated pathways, which have historically boosted access for 2,500+ annual melanoma deaths; instead, it focused narrowly on Makary's rhetoric. Synthesizing these, the episode reveals eroded institutional trust, where legitimate scientific critiques blend with external pressures, risking investor flight from oncology pipelines.